ACHIEVE: The Type 2 Diabetes Filing Nobody Is Watching
Foundayo's obesity approval was the headline. The larger commercial and clinical question is whether a once-daily oral GLP-1 gets approved for type 2 diabetes — and that file is moving now.
Findings
- Eli Lilly has stated it plans to submit an additional FDA application for orforglipron as a treatment for type 2 diabetes.
- The application is based on findings from the phase 3 ACHIEVE program, evaluating once-daily oral orforglipron for glycemic control and cardiometabolic outcomes in adults with type 2 diabetes.
- In a phase 2 study in adults with type 2 diabetes, orforglipron achieved a mean A1C reduction of up to 2.1% at 26 weeks, against 0.4% with placebo and 1.1% with dulaglutide.
- The obesity approval does not predict the diabetes outcome; they are separate evidentiary questions.
Obesity approvals get consumer attention. Diabetes approvals move more medicine. The type 2 diabetes population is larger, better covered by insurance, and managed through chronic prescribing relationships that produce far higher persistence than weight-management prescribing does.
Program status on the record
The phase 2 result, read carefully
In the phase 2 study in adults with type 2 diabetes, orforglipron achieved a mean reduction in A1C of up to 2.1% at 26 weeks, compared with 0.4% for placebo and 1.1% for dulaglutide.
Three caveats belong with that number. It is phase 2, and phase 3 results routinely differ. The phrase up to indicates a top-dose figure rather than a pooled result. And dulaglutide is a reasonable but not maximal comparator — it is not the strongest injectable incretin available.
Weight-management patients often accept injection as a tradeoff for results. Type 2 diabetes is managed for decades, frequently in older patients, alongside several other oral medications. Injection reluctance is a well-documented barrier to earlier incretin initiation. An oral agent with meaningful A1C reduction and no food or water timing restriction addresses a real adherence problem rather than a convenience preference.
What separates this from oral semaglutide
An oral semaglutide product for type 2 diabetes already exists. The differentiator is formulation constraint rather than novelty of route. Semaglutide is a peptide requiring an absorption enhancer and a strict administration routine around food and water. Orforglipron is a nonpeptide small molecule and can be taken at any time of day without those restrictions.
Whether that translates into better real-world glycemic outcomes is an adherence question that no trial has yet answered outside a study setting, where adherence is monitored and artificially high.
- Phase 3 ACHIEVE efficacy results and their relationship to the phase 2 signal.
- Cardiovascular outcome data, which for this class has become a de facto expectation rather than an optional endpoint.
- Whether the diabetes filing would also be routed through an expedited pathway.
- Pricing and formulary positioning for a diabetes indication, which typically differ substantially from weight-management pricing.
- Whether the safety profile in a diabetes population, with more comorbidity and polypharmacy, matches the obesity trial experience.
The wider program
Orforglipron is also being studied for obstructive sleep apnea and hypertension in adults with obesity. A separate master protocol is recruiting participants with obesity or overweight and osteoarthritis of the knee, with primary completion estimated for April 2028.
This is the standard playbook for a successful incretin: establish the primary indication, then pursue the comorbidity indications that expand the coverage argument. Each one is a separate approval decision on separate evidence, and none is guaranteed by the obesity approval.
Why we are tracking it
If the diabetes indication is approved, the practical consequences reach well beyond one product. It would put a convenient oral incretin into first-line diabetes prescribing conversations, where injection reluctance currently delays initiation. It would change the insurance-coverage picture, since diabetes indications are covered far more consistently than obesity indications. And it would further weaken any remaining clinical-need argument for compounded oral GLP-1 formulations.
Primary sources & citations
- MedCentral, reporting on Eli Lilly's stated plan to submit a type 2 diabetes application for orforglipron based on the phase 3 ACHIEVE program.
- Drugs.com FDA approval history for Foundayo (orforglipron), including phase 2 study NCT05048719 A1C results against placebo and dulaglutide.
- ClinicalTrials.gov records for orforglipron (LY3502970) master protocols, including the knee osteoarthritis program NCT07153471.
- US Food and Drug Administration press announcement on approval of Foundayo, April 1, 2026.
- Pharmacy Times, coverage of the orforglipron obesity approval.
Editorial note
Looking for a provider rather than a citation?
This site does not review or rank telehealth providers inside its research articles, and carries no provider links in article text. Our provider comparison grid, including how each one is monetized, lives on the homepage.
Open the provider grid